(secondQuint)24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia.

 The primary objective of the open-label extension phase was the long-term assessment of safety and tolerability of Extended Release (ER) OROS paliperidone (3 mg to 12 mg/day) in subjects (>65 years of age) with schizophrenia, and the secondary objective was the assessment of long-term efficacy.

 Paliperidone ER OROS(R) tablet formulation (3 to 12 mg/day) to be taken orally.

 24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia@highlight

The purpose of this open-label study was to evaluate the safety and tolerability of flexible doses of Extended Release OROS(R) Paliperidone in the treatment of geriatric subjects with schizophrenia after completion of the initial double blind study